# The Fink Family Office

> The Fink Family Office is a VC fund backing Biotechnology, Medical and Robotics. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Aug 2025
- Lead investor: 29%
- Last updated: Aug 2026

The Fink Family Office is a VC fund focused on Biotechnology and Medical. The Fink Family Office operates as a family investment office.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Robotics | 1 | 14% |
| Biopharma | 1 | 14% |
| Electronics | 1 | 14% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 57% |
| Pre-Seed | 1 | 14% |
| Funding Round | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M | Seed | Aug 28, 2025 |  |
| Argonaute RNA | Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. They show how their proprietary modification of smallinterfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. | $2.3M |  | Jul 17, 2024 |  |
| MitoRx Therapeutics | MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M | Seed | Dec 13, 2023 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M | Pre-Seed | Jan 17, 2023 |  |
| QV Bioelectronics | Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M | Seed | Jan 10, 2023 |  |
| cheMastery | CheMastery is a company that creates laboratory automation technology. They provide automation solutions for chemical laboratories in order to facilitate the manufacturing and R&D processes in the chemical sector. It makes science more effective and reliable for scientists in the chemical sector. |  | Seed | Nov 13, 2022 |  |
| MitoRx Therapeutics | MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. |  | Seed | Apr 25, 2022 |  |

7 of 7 investments shown.

## Co-investors
- [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures) — VC Fund, 10 deals together
- [Science Angel Syndicate](https://shizune.co/investors/profile/science-angel-syndicate) — VC Fund, 4 deals together
- [Elbow Beach Capital](https://shizune.co/investors/profile/elbow-beach-capital) — VC Fund, 3 deals together
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-venture-managers) — VC Fund, 2 deals together
- [Hermesa](https://shizune.co/investors/profile/hermesa) — VC Fund, 2 deals together
- [Longevitytech.fund](https://shizune.co/investors/profile/longevitytech-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does The Fink Family Office invest in?

The Fink Family Office invests primarily in Biotechnology, Medical and Robotics startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did The Fink Family Office last invest?

The most recent investment recorded for The Fink Family Office closed in Aug 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co